-
1001
Human soft tissue sarcomas harbor an intratumoral viral microbiome which is linked with natural killer cell infiltrate and prognosis
Published 2023-01-01“…Journal for ImmunoTherapy of Cancer…”
Get full text
Article -
1002
First-in-human phase I trial of the bispecific CD47 inhibitor and CD40 agonist Fc-fusion protein, SL-172154 in patients with platinum-resistant ovarian cancer
Published 2025-01-01“…Journal for ImmunoTherapy of Cancer…”
Get full text
Article -
1003
Modulation of myeloid and T cells in vivo by Bruton’s tyrosine kinase inhibitor ibrutinib in patients with metastatic pancreatic ductal adenocarcinoma
Published 2023-01-01“…Journal for ImmunoTherapy of Cancer…”
Get full text
Article -
1004
Therapeutic depletion of CCR8+ tumor-infiltrating regulatory T cells elicits antitumor immunity and synergizes with anti-PD-1 therapy
Published 2021-02-01“…Journal for ImmunoTherapy of Cancer…”
Get full text
Article -
1005
Leveraging mRNA technology for antigen based immuno-oncology therapies
Published 2025-01-01“…Journal for ImmunoTherapy of Cancer…”
Get full text
Article -
1006
Immunogenicity in humans of a transdermal multipeptide melanoma vaccine administered with or without a TLR7 agonist
Published 2021-05-01“…Journal for ImmunoTherapy of Cancer…”
Get full text
Article -
1007
Targeted inhibition of Aurora kinase A promotes immune checkpoint inhibition efficacy in human papillomavirus-driven cancers
Published 2025-01-01“…Journal for ImmunoTherapy of Cancer…”
Get full text
Article -
1008
Neoantigen-specific stimulation of tumor-infiltrating lymphocytes enables effective TCR isolation and expansion while preserving stem-like memory phenotypes
Published 2024-05-01“…Journal for ImmunoTherapy of Cancer…”
Get full text
Article -
1009
Haemophagocytic lymphohistiocytosis in patients treated with immune checkpoint inhibitors: analysis of WHO global database of individual case safety reports
Published 2019-05-01“…Journal for ImmunoTherapy of Cancer…”
Get full text
Article -
1010
CD4 CAR-T cells targeting CD19 play a key role in exacerbating cytokine release syndrome, while maintaining long-term responses
Published 2023-01-01“…Journal for ImmunoTherapy of Cancer…”
Get full text
Article -
1011
CAR T-cell detection scoping review: an essential biomarker in critical need of standardization
Published 2023-05-01“…Journal for ImmunoTherapy of Cancer…”
Get full text
Article -
1012
HDAC and MEK inhibition synergistically suppresses HOXC6 and enhances PD-1 blockade efficacy in BRAFV600E-mutant microsatellite stable colorectal cancer
Published 2025-01-01“…Journal for ImmunoTherapy of Cancer…”
Get full text
Article -
1013
CD4 T cell depletion increases memory differentiation of endogenous and CAR T cells and enhances the efficacy of Super2 and IL-33-armored CAR T cells against solid tumors
Published 2025-02-01“…Journal for ImmunoTherapy of Cancer…”
Get full text
Article -
1014
Pembrolizumab hybrid dosing is non-inferior to flat dosing in advanced non-small cell lung cancer: a real-world, retrospective bicenter cohort study
Published 2025-02-01“…Journal for ImmunoTherapy of Cancer…”
Get full text
Article -
1015
T lymphocytes induce human cancer cells derived from solid malignant tumors to secrete galectin-9 which facilitates immunosuppression in cooperation with other immune checkpoint pr...
Published 2023-01-01“…Journal for ImmunoTherapy of Cancer…”
Get full text
Article -
1016
Phase I study of intratumoral administration of CV8102 in patients with advanced melanoma, squamous cell carcinoma of the skin, squamous cell carcinoma of the head and neck, or ade...
Published 2025-02-01“…Journal for ImmunoTherapy of Cancer…”
Get full text
Article -
1017
Comparison of PD-L1 tumor cell expression with 22C3, 28-8, and SP142 IHC assays across multiple tumor types
Published 2022-10-01“…Journal for ImmunoTherapy of Cancer…”
Get full text
Article -
1018
Lactylation-driven TNFR2 expression in regulatory T cells promotes the progression of malignant pleural effusion
Published 2024-12-01“…Journal for ImmunoTherapy of Cancer…”
Get full text
Article -
1019
-
1020
Lambert-Eaton Myasthenic Syndrome Secondary to Nivolumab and Ipilimumab in a Patient with Small-Cell Lung Cancer
Published 2019-01-01“…He was therefore started on immunotherapy with nivolumab every 2 weeks and ipilimumab every 6 weeks. …”
Get full text
Article